BioCardia, Inc. (NASDAQ:BCDA) Sees Significant Drop in Short Interest

BioCardia, Inc. (NASDAQ:BCDA) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 83,400 shares, a decline of 19.5% from the November 30th total of 103,600 shares. Based on an average trading volume of 55,000 shares, the short-interest ratio is currently 1.5 days. Currently, 2.2% of the company’s shares are short sold.

BioCardia Price Performance

Shares of NASDAQ BCDA traded up $0.03 during midday trading on Tuesday, hitting $2.18. The company’s stock had a trading volume of 55,586 shares, compared to its average volume of 267,163. The firm has a market capitalization of $9.99 million, a price-to-earnings ratio of -0.52 and a beta of 1.25. The business’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $2.65. BioCardia has a 1 year low of $1.63 and a 1 year high of $10.79.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.